前列腺癌PSMA靶向PET中PSMA-RADS-3A与3B可疑摄取的随访预测价值
该回顾性分析纳入110例前列腺癌患者,其中56例存在PSMA-RADS-3A或3B不确定病灶,22例有充分随访(中位10个月)。46个可评估病灶中58.7%随访出现提示真阳性的改变,PSMA-RADS-3A为75.0%,PSMA-RADS-3B为21.4%。SUVmax及病灶/血池比值在进展与稳定病灶间重叠。
要点
- PSMA-RADS-3A病灶随访真阳性率75.0%,高于PSMA-RADS-3B的21.4%。
- 两类不确定病灶均可出现恶性证据,属真正不确定类别。
- SUVmax及病灶/血池比值在真阳性与稳定病灶间有重叠。
核心结论
- PSMA-RADS-3A和3B均为真正不确定类别,随访中均可见恶性证据,且3A较3B更可能为前列腺癌部位,指导治疗时应考虑此信息。
研究设计与样本
- 回顾性分析110例前列腺癌患者,采用18F-DCFPyL PET/CT并按PSMA-RADS 1.0分类,56例(50.9%)存在PSMA-RADS-3A或3B不确定病灶,22例(39.3%)有充分随访纳入分析,中位随访10个月(范围3-22个月)。
主要发现
- 46个可评估不确定病灶中27个(58.7%)随访出现提示前列腺癌真阳性的改变,包括PSMA-RADS-3A 24/32(75.0%)和PSMA-RADS-3B 3/14(21.4%)。
- 随访出现恶性改变与保持不变的病灶之间,SUVmax及病灶SUVmax/血池SUVmean比值范围有重叠。
- 存在额外明确前列腺癌病灶(PSMA-RADS-4和PSMA-RADS-5)增加不确定病灶随访表现为真阳性的可能性。
关键数值与推荐
- PSMA-RADS-3A(软组织)和PSMA-RADS-3B(骨)为不确定类别。
- 22例患者中46个病灶可评估:PSMA-RADS-3A 32个、PSMA-RADS-3B 14个。
- 随访真阳性率:PSMA-RADS-3A 75.0%(24/32) vs PSMA-RADS-3B 21.4%(3/14)。
临床怎么用
- 作者认为PSMA-RADS-3A较3B更可能代表前列腺癌部位,此信息在指导患者治疗时应予以考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted PET imaging has become commonly used in patients with prostate cancer (PCa). The PSMA reporting and data system version 1.0 (PSMA-RADS version 1.0) categorizes lesions on the basis of the likelihood of PCa involvement, with PSMA-RADS-3A (soft-tissue) and PSMA-RADS-3B (bone) lesions being indeterminate for the presence of disease. We retrospectively reviewed the imaging follow-up of such lesions to determine the rate at which they underwent changes suggestive of underlying PCa. Methods: PET/CT imaging with 18F-DCFPyL was performed in 110 patients with PCa, and lesions were categorized according to PSMA-RADS version 1.0. The study reported herein is a retrospective analysis of those patients. Fifty-six of 110 (50.9%) patients were determined to have indeterminate PSMA-RADS-3A or PSMA-RADS-3B lesions, and 22 of 56 (39.3%) patients had adequate follow-up to be included in the analysis (median follow-up time was 10 mo [range, 3-22 mo]). The SUVmax of the lesions was obtained, and the ratios of SUVmax of the lesions to SUVmean of blood pool (SUVmax-lesion/SUVmean-bloodpool) were calculated. Predetermined criteria were used to evaluate the PSMA-RADS-3A and PSMA-RADS-3B lesions on follow-up imaging to determine whether they demonstrated evidence of underlying malignancy. Results: A total of 46 lesions in 22 patients were considered indeterminate for PCa (i.e., PSMA-RADS-3A [32 lesions] or PSMA-RADS-3B [14 lesions]) and were evaluable on follow-up imaging. Twenty-seven of 46 (58.7%) lesions demonstrated changes suggesting they were true-positive for PCa. These lesions included 24 of 32 (75.0%) PSMA-RADS-3A lesions and 3 of 14 (21.4%) lesions categorized as PSMA-RADS-3B. The ranges of SUVmax and SUVmax-lesion/SUVmean-bloodpool overlapped between those lesions demonstrating changes consistent with malignancy on follow-up imaging and those lesions that remained unchanged on follow-up. The presence of additional definitive sites of PCa (PSMA-RADS-4 and PSMA-RADS-5) increases the likelihood that indeterminate lesions will manifest as true-positive on follow-up imaging. Conclusion: PSMA-RADS-3A and PSMA-RADS-3B lesions are truly indeterminate in that proportions of findings in both categories demonstrate evidence of malignancy on follow-up imaging. Overall, PSMA-RADS-3A lesions are more likely than PSMA-RADS-3B lesions to represent sites of PCa, and this information should be considered when guiding patient therapy.
引用
- Yin Y, Werner RA, Higuchi T, et al. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. J Nucl Med. 2018. PMID: 30190303. doi:10.2967/jnumed.118.217653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。